Emergen Research has introduced its latest Targeted DNA RNA Sequencing market research content, a comprehensive solution designed to support businesses in understanding complex industry dynamics and making informed strategic decisions. In today’s rapidly evolving business landscape, organizations must rely on accurate data and insightful analysis to stay competitive. This research content addresses that need by offering a well-rounded perspective on the Targeted DNA RNA Sequencing market, combining both qualitative and quantitative insights.
One of the key strengths of this research lies in its ability to present data in a meaningful and actionable way. Rather than overwhelming users with raw information, the report focuses on delivering insights that can be directly applied to business strategies. This approach allows organizations to identify growth opportunities, optimize their operations, and improve overall performance.
The Targeted DNA RNA Sequencing Market is expected to grow from an estimated USD 11.3 billion in 2024 to USD 59.2 billion in 2035, at a CAGR of 20.20%.
Government-sponsored initiatives and organisational programs are critical factors driving the Targeted DNA and RNA Sequencing Market. Agencies such as the National Institutes of Health (NIH) and the National Institute of Environmental Health Sciences (NIEHS) have helped cultivate research and innovation.
The NIH’s National Human Genome Research Institute (NHGRI), for instance, has invested heavily in refining sequencing technologies to improve diagnostic resolution and decrease costs. Such programmes are not only advancing the field but are also creating accessible healthcare solutions through genomic medicine.
In 2024, NIEHS and NHGRI co-hosted a workshop on RNA sequencing technologies with an emphasis on epi transcriptomics, which promises insight into complex diseases such as cancer and neurodegenerative disorders.
Government reports also reveal that targeted approaches, including the Twist Viral Research Panel, were 10–100× more sensitive than untargeted sequencing and had lower total costs for smaller sample sizes. In particular, sequencing a batch of 23 samples with the Twist panel is less expensive than the untargeted Illumina approach and, thus, easier to generalise.
However, the reliance on government-supported frameworks is increasing. It is reported that NIH-funded sequencing projects increased diagnostic yields for rare diseases by 35% in 2023, and the adoption of targeted sequencing reduced average costs of sequencing by up to 40%. These achievements indicate the importance of institutional support in propelling technological innovation and making markets more accessible.
The Targeted DNA RNA Sequencing market research content is developed by experienced analysts who utilize advanced methodologies and extensive data analysis. The content includes a variety of resources such as in-depth reports, whitepapers, case studies, and trend analyses. These materials cover multiple industries including healthcare, technology, finance, consumer goods, and manufacturing, making the research highly versatile and relevant.
Request Free Sample Copy (To Understand the Complete Structure of this Report [Summary + TOC]) @ https://www.emergenresearch.com/request-free-sample/4627
Another important aspect of the report is its detailed analysis of market drivers and influencing factors. The study examines how technological advancements, economic conditions, and evolving consumer preferences impact the growth of the Targeted DNA RNA Sequencing market. By understanding these factors, businesses can align their strategies with current trends and position themselves for long-term success.
By Product Outlook (Revenue, USD Billion; 2020-2035)Â
- NGS
- Method
- Exome Sequencing
- Enrichment Sequencing
- Amplicon Sequencing
- Others
- Application
- Cancer Gene Sequencing
- Inherited Disease Screening
- Drug Development
- Forensic Genomics
- 16S ribosomal RNA (rRNA) sequencing
- Others
- Method
By Workflow Outlook (Revenue, USD Billion; 2020-2035)Â
- Pre-sequencing
- Sequencing
- Data Analysis
By Application Outlook (Revenue, USD Billion; 2020-2035)Â
- Human Biomedical Research
- Plant & Animal Sciences
- Drug Discovery
- Others
By Type Outlook (Revenue, USD Billion; 2020-2035)Â
- DNA Based Targeted Sequencing
- RNA Based Targeted Sequencing
By End-use Outlook (Revenue, USD Billion; 2020-2035)Â
- Academic Research
- Hospitals & Clinics
- Pharma & Biotech Entities
- Others
By Regional Outlook (Revenue, USD Billion; 2020-2035)Â
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Benelux
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East and Africa
- Saudi Arabia
- UAE
- South Africa
- Turkey
- Rest of MEA
In addition to identifying growth drivers, the report also evaluates potential challenges that may affect the market. These include fluctuations in demand, changes in regulatory environments, and shifts in consumer behavior. By providing a balanced analysis, the research enables businesses to prepare for uncertainties and develop resilient strategies.
Market segmentation:-
The segmentation analysis is another critical component of the report. By breaking down the Targeted DNA RNA Sequencing market into different segments based on product types, applications, and end-user industries, the study provides a clear understanding of market structure. This segmentation allows businesses to identify high-growth areas and focus their efforts where they are most likely to achieve success.
The outlook for the Targeted DNA and RNA Sequencing Market remains positive due to significant government funding and progress in sequencing technologies, especially in cancer research and inherited disease screening. Asia-Pacific is the fastest-growing region, with increased government support fueling market expansion.
In terms of competitive analysis, leading companies such as Illumina, Thermo Fisher Scientific, and Pacific Biosciences are driving market innovation, supported by government partnerships and research programs, strengthening their market positions.
In June 2024, Bio-Rad launched the ddSEQ Single-Cell 3′ RNA-Seq Kit, designed to support single-cell gene expression research. This kit allows researchers to efficiently and affordably analyse gene expression at the single-cell level, potentially advancing research in oncology, immunology, and other fields.
Some of the key companies in the global Targeted DNA RNA Sequencing market include:
- Illumina
- F. Hoffman-La Roche Ltd.
- QIAGEN
- Thermo Fisher Scientific, Inc.
- Bio-Rad Laboratories, Inc.
- Oxford Nanopore Technologies
- PierianDx
- Genomatix GmbH
- DNASTAR, Inc.
- Perkin Elmer, Inc.
Competitive landscape:-
The report also offers a comprehensive overview of the competitive landscape. Understanding the strategies and performance of key players is essential for maintaining a competitive edge. The study provides detailed insights into major companies operating in the Targeted DNA RNA Sequencing market, including their product portfolios, pricing strategies, and recent developments such as mergers, acquisitions, collaborations, and technological innovations.
Increasing Government Investments in Genomic Research Infrastructure Boost the Market Growth
Government investments in genomics research infrastructure greatly advance the Targeted DNA and RNA Sequencing Market. The Horizon Europe program, set up by the European Union, invested billions of euros to fuel genomics into further advancements for precision medicine and public health initiatives.
In the United States, the NIH’s All of Us Research Program focuses on sequencing more than one million people’s genomes; it has focused on targeted sequencing to identify genetic tendencies toward diseases. Such megaprojects are also encouraging the use of inexpensive and highly sensitive sequencing technologies.
Government-funded projects are showing impressive increases in the efficiency of research. NIH data show that the sequencing technologies funded by their initiatives have brought down the cost of sequencing from over $10 million per genome in 2006 to less than $1,000 by 2024.
Similarly, targeted RNA sequencing initiatives funded by the NIEHS have improved diagnostic accuracy for rare diseases by 45% over untargeted methods. This shows how infrastructure and funding from governments are addressing both affordability and accessibility in the market.
Custom Requirements can be requested for this Report [Customization Available] @ https://www.emergenresearch.com/request-for-customization/4627
Another notable feature of the research is its focus on actionable recommendations. The report provides practical guidance that businesses can implement to enhance their operations and improve their market position. These recommendations are tailored to address specific challenges and opportunities within the Targeted DNA RNA Sequencing market, making them highly relevant and effective.
Browse Full Report Description + Research Methodology + Table of Content + Infographics @ https://www.emergenresearch.com/industry-report/targeted-dna-rna-sequencing-market
The Targeted DNA RNA Sequencing market research content is designed to serve a diverse audience, including key market players, investors, venture capitalists, and organizations of all sizes. It also provides valuable insights for research institutions, consulting firms, and policymakers, enabling them to make informed decisions and develop effective strategies.
The report emphasizes the importance of staying updated with the latest market trends. Emergen Research ensures that its content is regularly updated, providing businesses with access to the most current information. This allows organizations to adapt quickly to changes and maintain their competitive advantage.
About Emergen Research
Emergen Research is a leading market research and consulting company that provides syndicated reports, customized research solutions, and strategic advisory services. The company focuses on delivering accurate and data-driven insights that help businesses understand market trends, analyze consumer behavior, and achieve sustainable growth.
Contact Us:
Eric Lee
Corporate Sales Specialist
Emergen Research | Web: https://www.emergenresearch.com/
Direct Line: +1 (604) 757-9756
E-mail: sales@emergenresearch.com